Literature DB >> 26883150

Isatin derivatives with activity against apoptosis-resistant cancer cells.

Nikolai M Evdokimov1, Igor V Magedov2, Dominic McBrayer2, Alexander Kornienko3.   

Abstract

In a search of small molecules active against apoptosis-resistant cancer cells, a series of isatin-based heterocyclic compounds were synthesized and found to inhibit proliferation of cancer cell lines resistant to apoptosis. The synthesis of these compounds involved a condensation of commercially available, active methylene heterocycles with isatin proceeding in moderate to excellent yields. The heterocyclic scaffolds prepared in the current investigation appear to be a useful starting point for the development of agents to fight cancers with apoptosis resistance, and thus, associated with dismal prognoses.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer activity; Apoptosis resistance; Cytotoxic compounds; Indirubin; Isatin

Mesh:

Substances:

Year:  2016        PMID: 26883150      PMCID: PMC4775416          DOI: 10.1016/j.bmcl.2016.02.015

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

1.  Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis.

Authors:  Hermann Brenner
Journal:  Lancet       Date:  2002-10-12       Impact factor: 79.321

Review 2.  Thiazolidinediones: a new class of antidiabetic drugs.

Authors:  C Day
Journal:  Diabet Med       Date:  1999-03       Impact factor: 4.359

Review 3.  Present and potential future issues in glioblastoma treatment.

Authors:  Florence Lefranc; Niloufar Sadeghi; Isabelle Camby; Thierry Metens; Olivier Dewitte; Robert Kiss
Journal:  Expert Rev Anticancer Ther       Date:  2006-05       Impact factor: 4.512

4.  Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells.

Authors:  Sangkil Nam; Ralf Buettner; James Turkson; Donghwa Kim; Jin Q Cheng; Stephan Muehlbeyer; Frankie Hippe; Sandra Vatter; Karl-Heinz Merz; Gerhard Eisenbrand; Richard Jove
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

5.  3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents.

Authors:  Yoan Ferandin; Karima Bettayeb; Marina Kritsanida; Olivier Lozach; Panagiotis Polychronopoulos; Prokopios Magiatis; Alexios-Leandros Skaltsounis; Laurent Meijer
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

Review 6.  Why does cytotoxic chemotherapy cure only some cancers?

Authors:  Philip Savage; Justin Stebbing; Mark Bower; Tim Crook
Journal:  Nat Clin Pract Oncol       Date:  2008-11-04

Review 7.  Anoikis resistance and tumor metastasis.

Authors:  Craig D Simpson; Kika Anyiwe; Aaron D Schimmer
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo.

Authors:  Kazumi Sugihara; Shigeyuki Kitamura; Tsuyoshi Yamada; Takashige Okayama; Shigeru Ohta; Keisuke Yamashita; Mineo Yasuda; Yoshiaki Fujii-Kuriyama; Ken'ich Saeki; Saburo Matsui; Tomonari Matsuda
Journal:  Biochem Biophys Res Commun       Date:  2004-05-28       Impact factor: 3.575

10.  The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.

Authors:  Véronique Mathieu; Christine Pirker; Elisabeth Martin de Lassalle; Mathieu Vernier; Tatjana Mijatovic; Nancy DeNeve; Jean-François Gaussin; Mischael Dehoux; Florence Lefranc; Walter Berger; Robert Kiss
Journal:  J Cell Mol Med       Date:  2009-02-20       Impact factor: 5.310

View more
  7 in total

1.  Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies.

Authors:  Mohammed S Taghour; Hazem Elkady; Wagdy M Eldehna; Nehal M El-Deeb; Ahmed M Kenawy; Eslam B Elkaeed; Aisha A Alsfouk; Mohamed S Alesawy; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 2.  A Mini Review on Isatin, an Anticancer Scaffold with Potential Activities against Neglected Tropical Diseases (NTDs).

Authors:  Shefali Chowdhary; Amandeep Arora; Vipan Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

3.  The influence of substituents on the reactivity and cytotoxicity of imidazothiazolotriazinones.

Authors:  Galina A Gazieva; Alexei N Izmest'ev; Lada V Anikina; Sergey A Pukhov; Marina E Meshchaneva; Dmitry V Khakimov; Natalya G Kolotyrkina; Angelina N Kravchenko
Journal:  Mol Divers       Date:  2018-03-14       Impact factor: 2.943

4.  Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.

Authors:  Olga Fedorova; Alexandra Daks; Varvara Petrova; Alexey Petukhov; Larissa Lezina; Oleg Shuvalov; Pavel Davidovich; Darya Kriger; Ekaterina Lomert; Dmitry Tentler; Victor Kartsev; Burhan Uyanik; Vyacheslav Tribulovich; Oleg Demidov; Gerry Melino; Nickolai A Barlev
Journal:  Cell Cycle       Date:  2018-09-05       Impact factor: 4.534

5.  Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.

Authors:  Ashraf N Abdalla; Miriana Di Stefano; Giulio Poli; Tiziano Tuccinardi; Ammar Bader; Antonio Vassallo; Mohamed E Abdallah; Mahmoud Zaki El-Readi; Bassem Refaat; Alanood S Algarni; Rizwan Ahmad; Hamad M Alkahtani; Alaa A-M Abdel-Aziz; Adel S El-Azab; Aljawharah Alqathama
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

6.  Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.

Authors:  Mohammed S Taghour; Hazem Elkady; Wagdy M Eldehna; Nehal El-Deeb; Ahmed M Kenawy; Eslam B Elkaeed; Bshra A Alsfouk; Mohamed S Alesawy; Dalal Z Husein; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  PLoS One       Date:  2022-09-23       Impact factor: 3.752

7.  Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, Cytotoxicity and ROS Generation Ability.

Authors:  Vladimir K Novotortsev; Maxim E Kukushkin; Viktor A Tafeenko; Dmitry A Skvortsov; Marina A Kalinina; Roman V Timoshenko; Nelly S Chmelyuk; Liliya A Vasilyeva; Boris N Tarasevich; Petr V Gorelkin; Alexander S Erofeev; Alexander G Majouga; Nikolai V Zyk; Elena K Beloglazkina
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.